ClinicalTrials.gg
RecruitingNCT07768345Updated Oct 14, 2026

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

A Phase 3 interventional study of RSVpreF Vaccine in Respiratory Syncytial Virus (RSV), sponsored by Pfizer. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 14, 2026Site recruiting status changed12 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults.

This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol.

All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine.

Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants ≥18 years of age who are/were at the time of initial RSVpreF vaccination, per study protocol, and will be grouped based on prior RSV vaccination history:
  • Group 1 will include participants naïve to any RSV vaccine.
  • Group 2 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 1 year (9 to 15 months) prior to enrollment.
  • Group 3 will include participants who received a single prior dose of RSVpreF (Abrysvo) approximately 2 years (21 to 27 months) prior to enrollment.
  • Group 4 will include participants who previously received 2 doses of RSVpreF in Study C3671023 Substudy B approximately 3 years (36 to 42 months) prior to enrollment.
  • Participants should have a ≥12 months (365 days) in the opinion of the investigator at enrollment.

Key Exclusion Criteria:

  • Prior history of any subtype of Guillain-Barré Syndrome (GBS) of any etiology.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any components of the study intervention(s).
  • Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions, within 90 days prior to study enrollment or suspected chronic humoral or cellular rejection.
  • Receipt of B-cell depleting therapies within 180 days prior to initial study vaccination.

Refer to the study contact for further eligibility details.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    Group 1

    RSVpreF Vaccine

    Biological: RSVpreF Vaccine

  • Experimental
    Group 2

    RSVpreF Vaccine

    Biological: RSVpreF Vaccine

  • Experimental
    Group 3

    RSVpreF Vaccine

    Biological: RSVpreF Vaccine

  • Experimental
    Group 4

    RSVpreF Vaccine

    Biological: RSVpreF Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local reactions

    Time frame: For up to 7 days after vaccination

  2. Percentage of participants reporting systemic events

    Time frame: For up to 7 days after vaccination

  3. Percentage of participants reporting adverse events

    Time frame: Through 1 month after vaccination

  4. Percentage of participants reporting newly diagnosed chronic medical conditions

    Time frame: Through 12 months after vaccination

  5. Percentage of participants reporting serious adverse events

    Time frame: Through 12 months after vaccination

  6. Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titer (GMT)

    Time frame: Before vaccination, 1 month, 6 months and 12 months after vaccination

  7. NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)

    Time frame: Before vaccination, 1 month, 6 months and 12 months after vaccination

Secondary outcomes

  1. Seroresponse rate of NTs for RSV A and RSV B

    Time frame: 1 month after revaccination

07

Study locations

13 of 17 sites recruiting
  • Kaiser Foundation Hospital LAMC
    Los Angeles, California 90027, United States
    Recruiting
  • Kaiser Permanente Los Angeles Medical center
    Los Angeles, California 90027, United States
    Recruiting
  • Kaiser Permanente
    Los Angeles, California 90027, United States
    Recruiting
  • George Washington University
    Washington D.C., District of Columbia 20037, United States
    Recruiting
  • The Hope Clinic of Emory University
    Decatur, Georgia 30030, United States
    Recruiting
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
  • University of Iowa, Infectious Disease Research Laboratory, VA Medical Center
    Iowa City, Iowa 52246, United States
    Recruiting
  • University of Maryland, Institute of Human Virology
    Baltimore, Maryland 21201, United States
    Recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • NYU Langone Health Vaccine Center
    New York, New York 10016, United States
    Recruiting
  • Rochester Clinical Research
    Rochester, New York 14609, United States
    Recruiting
  • University of Rochester Investigational Drug Services
    Rochester, New York 14642, United States
    Not yet recruiting
  • University of Rochester Medical Center-Infectious Diseases Research Clinic
    Rochester, New York 14642, United States
    Not yet recruiting
  • Duke Vaccine and Trials Unit
    Durham, North Carolina 27703, United States
    Not yet recruiting
  • Duke Clinics 2F, 2G
    Durham, North Carolina 27710, United States
    Not yet recruiting
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
    Recruiting
  • Epic Medical Research-Desoto
    DeSoto, Texas 75115, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 17, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Feb 2, 2028
CompletionEst.
Feb 2, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • The Hope Clinic of Emory University · Decatur, United StatesNot yet recruiting→Recruiting
  • Rochester Clinical Research · Rochester, United StatesNot yet recruiting→Recruiting
  • Altoona Center for Clinical Research · Duncansville, United StatesNot yet recruiting→Recruiting
Show 12 added (12 United States)
  • George Washington University · Washington D.C., United States
  • NYU Langone Health Vaccine Center · New York, United States
  • Duke Vaccine and Trials Unit · Durham, United States
  • Duke Clinics 2F, 2G · Durham, United States
  • Altoona Center for Clinical Research · Duncansville, United States
  • University of Iowa · Iowa City, United States
  • University of Iowa, Infectious Disease Research Laboratory, VA Medical Center · Iowa City, United States
  • University of Maryland, Institute of Human Virology · Baltimore, United States
  • Washington University School of Medicine · St Louis, United States
  • University of Rochester Investigational Drug Services · Rochester, United States
  • University of Rochester Medical Center-Infectious Diseases Research Clinic · Rochester, United States
  • Epic Medical Research-Desoto · DeSoto, United States
across 2 updates, Sep 25, 2026 – Oct 14, 2026
Show all 2 updates
  1. Oct 14, 2026
    7 sites added. Altoona Center for Clinical Research is now Recruiting
    Show 7 added (7 United States)
    • University of Iowa · Iowa City, United States
    • University of Iowa, Infectious Disease Research Laboratory, VA Medical Center · Iowa City, United States
    • University of Maryland, Institute of Human Virology · Baltimore, United States
    • Washington University School of Medicine · St Louis, United States
    • University of Rochester Investigational Drug Services · Rochester, United States
    • University of Rochester Medical Center-Infectious Diseases Research Clinic · Rochester, United States
    • Epic Medical Research-Desoto · DeSoto, United States
    + 1 other change: verification date
  2. Sep 25, 2026
    5 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • The Hope Clinic of Emory University · Decatur, United StatesNot yet recruiting→Recruiting
    • Rochester Clinical Research · Rochester, United StatesNot yet recruiting→Recruiting
    Show 5 added (5 United States)
    • George Washington University · Washington D.C., United States
    • NYU Langone Health Vaccine Center · New York, United States
    • Duke Vaccine and Trials Unit · Durham, United States
    • Duke Clinics 2F, 2G · Durham, United States
    • Altoona Center for Clinical Research · Duncansville, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07768345
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Aug 31, 2026
Primary completion
Feb 2, 2028 (estimated)
Completion
Feb 2, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion